Summary:
- Researchers at Johns Hopkins University have received significant federal funding to advance the development of a novel immunotherapy designed to treat Type 1 diabetes.
- The project focuses on utilizing regulatory T-cell therapy to restore immune tolerance, potentially halting the autoimmune destruction of insulin-producing beta cells in the pancreas.